Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes mellitus (Type I or II), as defined by the American Diabetes Association, 1997, lasting 1 year.~2. Patient must have a symmetric sensory-motor peripheral polyneuropathy of at least stage 2 attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy.~3. HbA1C \< 10%.~4. TSS \> 7.5 points.~5. NISLL \> 2 points.~6. Pain sensation (according to pin-prick sensitivity test) absent or decreased (NIS item 35 1).~7. Age range: 18 to 74 years. Inclusion criteria prior to randomisation~8. The TSS must be \> 5 points~9. The TSS range (maximum TSS minus minimum TSS during the run-in phase) must be less than 3 points to avoid inclusion of patients with rapidly oscillating symptoms.~10. At least 1 of the 4 symptoms of the TSS must have occurred continuously over the last 3 months.~11. Lack of compliance, i.e. below 85% or above 115% (Accordingly, 6 daily doses taken of the 7 daily doses scheduled for Phase A would be acceptable).~Exclusion Criteria:~Lack of suitability for the trial:~1. Proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpes neuralgias, etc.), with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both.~2. Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP.~3. Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality.~4. Myopathy of any cause.~5. Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia.~6. Patients with proliferating retinopathy requiring immediately therapy and impending blindness.~7. Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial.~8. Patients with any active neoplastic disease except basal cell carcinoma.~9. Patients with atrial fibrillation unless controlled and stabilised by medication.~10. Patients with clinically significant cardiac, pulmonary, gastrointestinal, haematological, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study.~11. Patients who have had organ transplants of any kind.~12. Patients with significant hepatic or renal disease (ASAT, ALAT or GGT \>2 times normal, serum creatinine \>1.8 mg/dL (\>159 mmol/l) for males or \>1.6 mg/dL (\>141 mmol/l) for females).~13. Patients with a recent history (within last 12 months) of drug or alcohol abuse.~14. Use of any investigational drug (participation in a clinical trial) within last 1 month.~15. History of severe or anaphylactic reaction to drugs, sulfur or biologic products.~16. Recent (within last 3 months) ketoacidosis or hypoglycaemia, necessitating hospital admission.~17. Antioxidant therapy (vitamins E \> 400 IU, C \> 200 mg, and beta-Carotene \> 30 mg) or pentoxyphylline within last 1 month before start of trial.~18. Use of thioctic acid (\> 50 mg), evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months.~19. Continued use of medications listed in section 6.2.3.~20. Bilateral sural nerve biopsies.~21. Existing foot ulcers.~    Safety concerns:~22. Pregnant or lactating females: Pregnancy as evidenced by positive b-hCG-test at screening visit or by testing performed at the study site on demand, or women of child-bearing potential not using adequate contraception.~23. History of allergic reaction to the study medication or its excipients.~    Administrative reasons:~24. Informed Consent is not signed or the patient has not complete competence to co-operate.~25. Any language barriers that can affect adequate understanding.~26. Anticipated non-availability for study visits/procedures.~27. Vulnerable subjects (such as persons kept in detention)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete